Abstract: 582 ATTAINMENT OF SINGLE/DUAL TREATMENT LEVELS FOR LDL-C AND NON-HDL-C, APOB, OR HS-CRP IN PATIENTS WITH METABOLIC SYNDROME (MS): EZETIMIBE(E)/SIMVASTATIN(S) VS ATORVASTATIN(A)

Autor: Ballantyne, C, Grundy, S, Hsueh, W, Parving, H, Robinson, J, Rosen, J, Lin, J, Lowe, R, Shah, A, Tomassini, J, Tershakovec, A
Zdroj: In Atherosclerosis (Supplements) (Component) 2009 10(2):e342-e343
Databáze: ScienceDirect
Externí odkaz: